Zhejiang Wecome Pharmaceutical Company Limited Logo

Zhejiang Wecome Pharmaceutical Company Limited

300878.SZ

(2.0)
Stock Price

18,40 CNY

-3.29% ROA

-4.22% ROE

-47.94x PER

Market Cap.

2.802.665.717,00 CNY

26.72% DER

1.27% Yield

-11.71% NPM

Zhejiang Wecome Pharmaceutical Company Limited Stock Analysis

Zhejiang Wecome Pharmaceutical Company Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zhejiang Wecome Pharmaceutical Company Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (28%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 ROE

The stock's ROE falls within an average range (1.05%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (0.77%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (2.83x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (899), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

Zhejiang Wecome Pharmaceutical Company Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zhejiang Wecome Pharmaceutical Company Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Zhejiang Wecome Pharmaceutical Company Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zhejiang Wecome Pharmaceutical Company Limited Revenue
Year Revenue Growth
2013 135.059.810
2014 153.276.986 11.89%
2015 207.742.355 26.22%
2016 282.091.952 26.36%
2017 406.528.838 30.61%
2018 577.652.191 29.62%
2019 641.800.892 10%
2020 622.766.990 -3.06%
2021 632.953.240 1.61%
2022 531.291.689 -19.13%
2023 462.252.205 -14.94%
2023 519.621.071 11.04%
2024 384.708.876 -35.07%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zhejiang Wecome Pharmaceutical Company Limited Research and Development Expenses
Year Research and Development Expenses Growth
2013 8.554.100
2014 9.675.800 11.59%
2015 12.933.500 25.19%
2016 14.364.120 9.96%
2017 15.828.534 9.25%
2018 16.399.833 3.48%
2019 21.160.217 22.5%
2020 20.408.872 -3.68%
2021 37.015.323 44.86%
2022 39.320.428 5.86%
2023 13.528.392 -190.65%
2023 42.798.186 68.39%
2024 12.990.932 -229.45%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zhejiang Wecome Pharmaceutical Company Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 20.627.956
2014 19.964.132 -3.33%
2015 28.645.260 30.31%
2016 18.702.270 -53.16%
2017 -8.179.819 328.64%
2018 -9.459.217 13.53%
2019 -7.907.022 -19.63%
2020 11.890.329 166.5%
2021 6.476.464 -83.59%
2022 6.927.942 6.52%
2023 99.047.407 93.01%
2023 8.213.769 -1105.87%
2024 -29.727.546 127.63%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zhejiang Wecome Pharmaceutical Company Limited EBITDA
Year EBITDA Growth
2013 30.289.518
2014 44.752.736 32.32%
2015 61.977.446 27.79%
2016 97.263.768 36.28%
2017 125.485.959 22.49%
2018 122.438.789 -2.49%
2019 165.010.794 25.8%
2020 179.237.205 7.94%
2021 137.606.778 -30.25%
2022 114.751.030 -19.92%
2023 81.007.778 -41.65%
2023 35.406.340 -128.79%
2024 8.888.560 -298.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zhejiang Wecome Pharmaceutical Company Limited Gross Profit
Year Gross Profit Growth
2013 66.321.734
2014 87.258.632 23.99%
2015 122.855.187 28.97%
2016 171.058.600 28.18%
2017 282.158.976 39.38%
2018 435.353.542 35.19%
2019 474.034.723 8.16%
2020 451.347.629 -5.03%
2021 428.577.032 -5.31%
2022 311.194.285 -37.72%
2023 301.657.206 -3.16%
2023 261.857.682 -15.2%
2024 196.350.768 -33.36%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zhejiang Wecome Pharmaceutical Company Limited Net Profit
Year Net Profit Growth
2013 19.748.013
2014 20.721.530 4.7%
2015 50.023.692 58.58%
2016 80.851.450 38.13%
2017 95.157.729 15.03%
2018 87.776.673 -8.41%
2019 126.012.754 30.34%
2020 135.815.760 7.22%
2021 96.495.377 -40.75%
2022 48.810.249 -97.69%
2023 18.919.920 -157.98%
2023 -8.038.558 335.36%
2024 -40.571.532 80.19%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zhejiang Wecome Pharmaceutical Company Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 1
2014 1 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zhejiang Wecome Pharmaceutical Company Limited Free Cashflow
Year Free Cashflow Growth
2013 14.506.872
2014 5.331.424 -172.1%
2015 -8.849.833 160.24%
2016 52.188.453 116.96%
2017 -13.036.291 500.33%
2018 -67.156.349 80.59%
2019 -2.214.214 -2932.97%
2020 -109.526.894 97.98%
2021 -238.841.567 54.14%
2022 -101.875.094 -134.45%
2023 -31.678.089 -221.59%
2023 -80.996.292 60.89%
2024 -21.869.808 -270.36%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zhejiang Wecome Pharmaceutical Company Limited Operating Cashflow
Year Operating Cashflow Growth
2013 25.982.100
2014 46.010.000 43.53%
2015 29.632.900 -55.27%
2016 100.154.851 70.41%
2017 29.003.913 -245.31%
2018 105.572.864 72.53%
2019 112.762.180 6.38%
2020 42.812.190 -163.39%
2021 -67.744.474 163.2%
2022 146.568.150 146.22%
2023 0 0%
2023 58.289.136 100%
2024 3.309.616 -1661.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zhejiang Wecome Pharmaceutical Company Limited Capital Expenditure
Year Capital Expenditure Growth
2013 11.475.227
2014 40.678.576 71.79%
2015 38.482.733 -5.71%
2016 47.966.398 19.77%
2017 42.040.204 -14.1%
2018 172.729.213 75.66%
2019 114.976.394 -50.23%
2020 152.339.084 24.53%
2021 171.097.094 10.96%
2022 248.443.244 31.13%
2023 31.678.089 -684.27%
2023 139.285.428 77.26%
2024 25.179.424 -453.17%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zhejiang Wecome Pharmaceutical Company Limited Equity
Year Equity Growth
2013 34.349.447
2014 78.221.067 56.09%
2015 130.044.759 39.85%
2016 210.896.209 38.34%
2017 306.053.939 31.09%
2018 393.830.612 22.29%
2019 519.843.367 24.24%
2020 1.384.388.473 62.45%
2021 1.409.024.683 1.75%
2022 1.411.518.796 0.18%
2023 1.484.811.086 4.94%
2023 1.407.408.799 -5.5%
2024 1.335.643.519 -5.37%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zhejiang Wecome Pharmaceutical Company Limited Assets
Year Assets Growth
2013 107.130.062
2014 173.042.723 38.09%
2015 221.885.579 22.01%
2016 315.142.893 29.59%
2017 479.735.606 34.31%
2018 641.121.096 25.17%
2019 875.868.201 26.8%
2020 1.628.782.391 46.23%
2021 1.693.307.837 3.81%
2022 1.913.773.127 11.52%
2023 2.084.644.059 8.2%
2023 2.046.636.530 -1.86%
2024 1.838.430.023 -11.33%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zhejiang Wecome Pharmaceutical Company Limited Liabilities
Year Liabilities Growth
2013 72.780.614
2014 94.821.655 23.24%
2015 91.840.819 -3.25%
2016 104.246.683 11.9%
2017 173.681.666 39.98%
2018 247.290.484 29.77%
2019 356.024.834 30.54%
2020 244.393.917 -45.68%
2021 284.283.154 14.03%
2022 502.254.330 43.4%
2023 599.832.973 16.27%
2023 639.227.731 6.16%
2024 461.819.168 -38.42%

Zhejiang Wecome Pharmaceutical Company Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.52
Net Income per Share
-0.41
Price to Earning Ratio
-47.94x
Price To Sales Ratio
5.61x
POCF Ratio
-1013.04
PFCF Ratio
-24.73
Price to Book Ratio
2.13
EV to Sales
5.7
EV Over EBITDA
-63.6
EV to Operating CashFlow
-1028.78
EV to FreeCashFlow
-25.12
Earnings Yield
-0.02
FreeCashFlow Yield
-0.04
Market Cap
2,80 Bil.
Enterprise Value
2,85 Bil.
Graham Number
9.27
Graham NetNet
1.15

Income Statement Metrics

Net Income per Share
-0.41
Income Quality
0.05
ROE
-0.04
Return On Assets
-0.03
Return On Capital Employed
-0.04
Net Income per EBT
0.93
EBT Per Ebit
1.04
Ebit per Revenue
-0.12
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.47
Operating Profit Margin
-0.12
Pretax Profit Margin
-0.13
Net Profit Margin
-0.12

Dividends

Dividend Yield
0.01
Dividend Yield %
1.27
Payout Ratio
-0.78
Dividend Per Share
0.25

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.8
Capex to Operating CashFlow
-39.96
Capex to Revenue
0.22
Capex to Depreciation
2.11
Return on Invested Capital
-0.03
Return on Tangible Assets
-0.03
Days Sales Outstanding
230.61
Days Payables Outstanding
75.12
Days of Inventory on Hand
185.33
Receivables Turnover
1.58
Payables Turnover
4.86
Inventory Turnover
1.97
Capex per Share
0.78

Balance Sheet

Cash per Share
2,26
Book Value per Share
9,69
Tangible Book Value per Share
9.25
Shareholders Equity per Share
9.28
Interest Debt per Share
2.54
Debt to Equity
0.27
Debt to Assets
0.19
Net Debt to EBITDA
-0.97
Current Ratio
4.46
Tangible Asset Value
1,31 Bil.
Net Current Asset Value
0,32 Bil.
Invested Capital
1596342300
Working Capital
0,61 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,33 Bil.
Average Payables
0,06 Bil.
Average Inventory
129284240.5
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zhejiang Wecome Pharmaceutical Company Limited Dividends
Year Dividends Growth
2021 1
2022 1 0%
2024 0 0%

Zhejiang Wecome Pharmaceutical Company Limited Profile

About Zhejiang Wecome Pharmaceutical Company Limited

Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of pharmaceutical products. The company also offers healthcare products, over-the-counter products, and Chinese medicines. It offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is based in Lishui, China.

CEO
Ms. Xiaoxia Kong
Employee
1.159
Address
No. 2, Songsong Road
Lishui, 323000

Zhejiang Wecome Pharmaceutical Company Limited Executives & BODs

Zhejiang Wecome Pharmaceutical Company Limited Executives & BODs
# Name Age
1 Ms. Jing Wang
Finance Director
70
2 Ms. Ting Zhu
Secretary & Non-Independent Director
70
3 Ms. Xiaoxia Kong
GM & Director
70
4 Mr. Jianming Wu
Deputy GM & Non-Independent Director
70

Zhejiang Wecome Pharmaceutical Company Limited Competitors